En route to early diagnosis of Alzheimer's disease - Are we there yet?

Trends in Biotechnology

Volumn 23, Issue 11, 2005, Pages 531-533

  Fradinger, Erica A ^a   Bitan, Gal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOASSAY; BIOTECHNOLOGY; DIAGNOSIS; DISEASES; OLIGOMERS; PROTEINS; RELIABILITY; SENSITIVITY ANALYSIS;

ALZHEIMER'S DISEASES; DIAGNOSTIC TOOLS; ELISA-BASED WORK; NANOBIOTECHNOLOGY;

DRUG PRODUCTS;

AMYLOID BETA PROTEIN; ANTIBODY; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; NANOPARTICLE; OLIGOMER;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIODIAGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 26944437908     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2005.09.002     Document Type: Short Survey

References (24)

1. L.E. Hebert Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 60 2003 1119 1122
2. L.E. Hebert Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050 Alzheimer Dis. Assoc. Disord. 15 2001 169 173
3. M. Citron Alzheimer's disease: treatments in discovery and development Nat. Neurosci. 5 Suppl. 2002 1055 1057
4. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging 18, S1-S2
5. SantaCruz, K.S. and Swagerty, D. (2001) Early diagnosis of dementia. Am. Fam. Physician 63, 703-713, 717-708
6. Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease. (1998) The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109-116
7. K. Kantarci, and C.R. Jack Jr Neuroimaging in Alzheimer disease: an evidence-based review Neuroimaging Clin. N. Am. 13 2003 197 209
8. P.J. Modrego Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy Am. J. Psychiatry 162 2005 667 675
9. D.H. Silverman, and A. Alavi PET imaging in the assessment of normal and impaired cognitive function Radiol. Clin. North Am. 43 2005 67 77
10. 1H MRI detection of amyloid β plaques in vivo Nat. Neurosci. 8 2005 527 533
11. D.J. Selkoe Alzheimers disease: A central role for amyloid J. Neuropathol. Exp. Neurol. 53 1994 438 447
12. D.J. Selkoe Alzheimer's disease: Genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
13. M.D. Kirkitadze Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies J. Neurosci. Res. 69 2002 567 577
14. N. Andreasen, and K. Blennow CSF biomarkers for mild cognitive impairment and early Alzheimer's disease Clin. Neurol. Neurosurg. 107 2005 165 173
15. C.E. Teunissen Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid Neurobiol. Aging 23 2002 485 508
16. H. Hampel Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Arch. Gen. Psychiatry 61 2004 95 102
17. P. Lewczuk Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau Neurobiol. Aging 25 2004 273 281
18. Y.M. Kuo Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains J. Biol. Chem. 271 1996 4077 4081
19. R. Kayed Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
20. Y. Gong Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. U. S. A. 100 2003 10417 10422
21. M. Pitschke Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy Nat. Med. 4 1998 832 834
22. P. Fortina Nanobiotechnology: the promise and reality of new approaches to molecular recognition Trends Biotechnol. 23 2005 168 173
23. J.M. Nam Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins Science 301 2003 1884 1886
24. D.G. Georganopoulou Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 102 2005 2273 2276